Genetics, tumor features and treatment response of breast cancer in Latinas

[1]  R. Jagsi,et al.  Treatment‐associated toxicities reported by patients with early‐stage invasive breast cancer , 2017, Cancer.

[2]  E. Podesta,et al.  Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice , 2016, Oncotarget.

[3]  J. L. Costa,et al.  Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry , 2016, Oncotarget.

[4]  P. Ashton-Prolla,et al.  Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. , 2016, Cancer genetics.

[5]  S. Narod,et al.  A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago , 2016, Breast Cancer Research and Treatment.

[6]  E. Perez-stable,et al.  Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry , 2016, Current Epidemiology Reports.

[7]  H. Gómez,et al.  A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). , 2016, Clinical breast cancer.

[8]  Luis Guzmán-AbiSaab,et al.  Frecuencia de mutación y de variantes de secuencia para los genes BRCA1 y BRCA2 en una muestra de mujeres colombianas con sospecha de síndrome de cáncer de mama hereditario: serie de casos , 2015 .

[9]  A. Obregon-Tito,et al.  Frequency of sequence mutations and variants for the BRCA1 and BRCA2 genes in a sample of Colombian women with suspected hereditary breast cancer syndrome: Case series , 2015 .

[10]  N. Keating,et al.  Breast cancer age at diagnosis patterns in four Latin American Populations: A comparison with North American countries. , 2015, Cancer epidemiology.

[11]  L. Pusztai,et al.  Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Monteiro,et al.  The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective , 2015, Breast Cancer Research and Treatment.

[13]  Christopher I. Li,et al.  Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[14]  S. Narod,et al.  Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru , 2015, Clinical genetics.

[15]  C. Parise,et al.  The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes , 2015, Journal of cancer epidemiology.

[16]  Maíra R. Rodrigues,et al.  Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations , 2015, Proceedings of the National Academy of Sciences.

[17]  B. Henderson,et al.  Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[18]  C. Villarreal-Garza,et al.  Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico. , 2015, Breast.

[19]  E. Winer,et al.  Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Weller,et al.  Reproductive risk factors differ among breast cancer patients and controls in a public hospital of Paraiba, northeast Brazil. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[21]  S. Narod,et al.  The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[22]  C. Pérez-Plasencia,et al.  Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico , 2015, Cancer.

[23]  Ping Sun,et al.  Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. , 2015, JAMA.

[24]  S. Narod,et al.  Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia , 2014, Hereditary Cancer in Clinical Practice.

[25]  E. John,et al.  Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California , 2014, Breast Cancer Research and Treatment.

[26]  R. Yelensky,et al.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.

[27]  Akbari,et al.  The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas , 2014, Clinical genetics.

[28]  E. Ziv,et al.  Genetic ancestry and risk of mortality among U.S. Latinas with breast cancer. , 2013, Cancer research.

[29]  J. Ferlay,et al.  Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.

[30]  B. Jönsson,et al.  A review of breast cancer care and outcomes in Latin America. , 2013, The oncologist.

[31]  E. John,et al.  Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Narod,et al.  BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica , 2012, Clinical genetics.

[33]  C. Pérez-Plasencia,et al.  Full-Exon Pyrosequencing Screening of BRCA Germline Mutations in Mexican Women with Inherited Breast and Ovarian Cancer , 2012, PloS one.

[34]  R. Sutphen,et al.  Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. , 2012, Cancer genetics.

[35]  S. Lakhan,et al.  Chronic traumatic encephalopathy: the dangers of getting "dinged" , 2012, SpringerPlus.

[36]  S. Narod,et al.  BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. , 2012, Gynecologic oncology.

[37]  A. Porco,et al.  BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. , 2012, Biological research.

[38]  L. Chow,et al.  Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. , 2011, European journal of cancer.

[39]  A. González-Angulo,et al.  Triple‐negative breast cancer in Hispanic patients , 2011, Cancer.

[40]  Bing-he Xu,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[41]  R. Wolff,et al.  Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States , 2011, Breast Cancer Research and Treatment.

[42]  R. Prentice,et al.  Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. , 2011, Journal of the National Cancer Institute.

[43]  G. Sabini,et al.  BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast–ovarian cancer families. Identification of novel mutations and unclassified variants , 2011, Breast Cancer Research and Treatment.

[44]  O. Díez,et al.  Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families , 2011, Breast Cancer Research and Treatment.

[45]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[46]  H. Gómez,et al.  Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. , 2010, Clinical breast cancer.

[47]  T. Byers,et al.  Comparative analysis of breast cancer risk factors among hispanic and non‐hispanic white women , 2010, Cancer.

[48]  E. Ziv,et al.  European Ancestry Is Positively Associated with Breast Cancer Risk in Mexican Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[49]  C. Parise,et al.  Variation in breast cancer subtypes with age and race/ethnicity. , 2008, Critical reviews in oncology/hematology.

[50]  David J Lee,et al.  Cancer Incidence in First Generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and New Latinos , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[51]  B. Ward,et al.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer , 2009, Cancer.

[52]  S. Koifman,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil. , 2009, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[53]  T. Rohan,et al.  Cancer disparities between mainland and island Puerto Ricans. , 2009, Revista panamericana de salud publica = Pan American journal of public health.

[54]  R. Kimerling,et al.  Adherence to recent screening mammography among Latinas: findings from the California Women's Health Survey. , 2009, Journal of women's health.

[55]  C. Vallejos,et al.  Guidelines for International Breast Health and Cancer Control – Implementation Supplement to Cancer Breast Cancer in Latin America Results of the Latin American and Caribbean Society of Medical Oncology / Breast Cancer Research Foundation Expert Survey , 2008 .

[56]  T. Byers,et al.  Differences in Estrogen Receptor Subtype According to Family History of Breast Cancer among Hispanic, but not Non-Hispanic White Women , 2008, Cancer Epidemiology Biomarkers & Prevention.

[57]  T. Byers,et al.  Family history and age at onset of breast cancer in Hispanic and non-Hispanic white women , 2008, Cancer Causes & Control.

[58]  G. Hortobagyi,et al.  Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women different? , 2008 .

[59]  G. Hortobagyi,et al.  PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer , 2008, Breast Cancer Research.

[60]  S. Narod,et al.  Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba , 2008, Familial Cancer.

[61]  E. Chang,et al.  Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype , 2007, Breast Cancer Research.

[62]  Alice S Whittemore,et al.  Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.

[63]  T. Byers,et al.  Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non‐Hispanic white women , 2007, International journal of cancer.

[64]  H. Greenlee,et al.  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  P. Neven,et al.  A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer , 2007, Clinical Cancer Research.

[66]  A. Monteiro,et al.  Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil , 2007, Breast Cancer Research and Treatment.

[67]  U. Hamann,et al.  High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia , 2007, Breast Cancer Research and Treatment.

[68]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[69]  T. Whelan,et al.  Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  E. Ziv,et al.  Genetic Ancestry and Risk Factors for Breast Cancer among Latinas in the San Francisco Bay Area , 2006, Cancer Epidemiology Biomarkers & Prevention.

[71]  J. Costantino,et al.  Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[72]  B. Pollock,et al.  Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  W. Willett,et al.  Folate, Vitamin B6, and Vitamin B12 Intake and the Risk of Breast Cancer Among Mexican Women , 2006, Cancer Epidemiology Biomarkers & Prevention.

[74]  K. Neville,et al.  Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. , 2006, The oncologist.

[75]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[76]  S. Neuhausen,et al.  Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families , 2005, Cancer Epidemiology Biomarkers & Prevention.

[77]  H. Nevanlinna,et al.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families , 2005, Human Genetics.

[78]  H. Barrera-Saldana,et al.  Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. , 2005, Salud publica de Mexico.

[79]  B. Pollock,et al.  Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy , 2005, Breast Cancer Research and Treatment.

[80]  D. Winn,et al.  Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands , 2003, Cancer and Metastasis Reviews.

[81]  J. Samet,et al.  Family history and risk of breast cancer in Hispanic and non-Hispanic women: the New Mexico Women's Health Study , 2001, Cancer Causes & Control.

[82]  M. Nagai,et al.  TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. , 2003, International journal of oncology.

[83]  K. Malone,et al.  Differences in breast cancer stage, treatment, and survival by race and ethnicity. , 2003, Archives of internal medicine.

[84]  O. Olopade,et al.  Breast cancer genetics in African Americans , 2003, Cancer.

[85]  G. Lenoir,et al.  BRCA1 and BRCA2 mutation analysis of early‐onset and familial breast cancer cases in Mexico , 2002, Human mutation.

[86]  Cathy J Bradley,et al.  Race, socioeconomic status, and breast cancer treatment and survival. , 2002, Journal of the National Cancer Institute.

[87]  L. Ries,et al.  Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups , 2001, Cancer.

[88]  N. Janin,et al.  The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript , 2001, Human mutation.

[89]  J. Garcia-conde,et al.  Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  S. Gapstur,et al.  Hormone receptor status of breast tumors in black, Hispanic, and non‐Hispanic white women: An analysis of 13,239 cases , 1996, Cancer.

[91]  I. Romieu,et al.  Breast cancer and lactation history in Mexican women. , 1996, American journal of epidemiology.

[92]  G M Clark,et al.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.